National and Kapodistrian University of Athens
Επιδημιολογικά - ιολογικά χαρακτηριστικά και αποτελεσματικότητα της αγωγής σε χρήστες τοξικών ουσιών με χρόνια ηπατίτιδα C
Abstract
dc:descriptionIntroduction: The prevalence of HCV infection is estimated at > 185 million worldwide, and undiagnosed infections can increase this prevalence by 20-30%. Aim: To evaluate a) HCV genotype distribution in chronic HCV-infected patients and b) the sustained virological response (SVR), at least 24 weeks after the end of treatment of chronic HCV – infected patients treated with Peginterferon/Ribavirin, presenting in a referral center for viral hepatitis of a public hospital in Athens, Greece within the last 6 years, September 2010- October 2016. Method: This is a non-intervention observational study in patients with chronic hepatitis C (PWID – people who inject drugs or not PWID), with or without HIV coinfection, with or without a history of previous antiviral therapy.The sample consisted of 660 patients (consequitive patients) with anti-HCV positive / 647 HCV-RNA positive intravenous drug users - IDUs or non-IDUs (transmission via blood transfusion or blood products, or via a cryprescriptional pathway), with or without co-infection of HIV, with or without a history of previous antiviral treatment and who had at least 2 recorded visits and completing an epidemiological report.The collection of data (epidemiological, somatometric, haematological - biochemical, virological characteristics) for patients who completed the treatment was performed retrospectively, 2000-2010.The collection of data for patients who were included in the study and whether or not have followed the treatment was prospective, 2010-2016.Results: 660 anti-HCV(+)/ 647 HCV-RNA(+) (647 patients with chronic HCV infection) (group A: 346 PWID, 67.9% males, mean age 37.5 years, mean BMI 24.2, mean HCV-RNA 286.000 IU/ml and group B: 301 non-PWID, 46.2% males, mean age 48.3 years, mean BMI 25.2, mean HCV-RNA 403.700 IU/ml ) were evaluated for HCV genotype. Among PWID, 108 (33.5%) reported intravenous drug use beginning before 1990 (subgroup A1) and the rest 238 (66.5%) of them after 1990 (subgroup A2). 136 PWID (39.6% of PWID) and 115 non – PWID (38.2%) are treated with Peginterferon/Ribavirin.From the sample, 98 patients (14.8%) had liver cirrhosis. Genotype 3 was dominant among group A patients (58.3%) followed by genotype 1 (27.1%) and genotype 4 (13.8%) whereas genotype 1 was dominant among group B patients (53.2%) followed by genotype 4 (19.7%) and genotype 3 (17%). The vast majority of genotype 1 infection among PWID (81.8%) presented the subtype 1a whereas subtype 1b was observed in the majority of genotype 1 infections among non-PWID (83.9%, p<0.001). It is important to note that 80% of genotype 3 infections among PWID observed in the subgroup A2 whereas 69% of genotype 4 infections among PWID observed in the subgroup A1. Genotype 1 infections among PWID were almost equally distributed in the subgroup A1 (41.7%) as well as in the subgroup A2 (58.3%). Sustained Virological Response (SVR) was observed in 63.4% (23/36) and 36.4% (20/55) of genotype 1 patients in groups A and B respectively (p <0.001), 54.3% (19/35) of genotype 4 patients and 80.6% (79/98) of genotype 3 patients. In the multivariable analysis, only the absence of cirrhosis (OR = 9.442, p = 0.014) was strongly related to the achievement of SVR in all patients and in addition the subtype 1a relative to 1b (OR = 3.309, p = 0.055) in genotype 1 patients. Conclusions: The genotype distribution and the dominant subtypes among PWID were determined by the route of transmission of the infection and the period of intravenous drug use beginning among PWID. Genotype 1 (especially subtype 1b) represent the dominant genotype among non-PWID and genotype 3 the dominant one among PWID in Greece. Genotype 1 (mainly subtype 1a) and genotype 4 infections observed almost exclusively in PWID who reported intravenous drug use beginning before 1990 whereas genotype 3 is responsible for the vast majority of infections among PWID who reported drug use beginning after 1990. Although PEG / RIBA therapy is used in less than 40% of patients with chronic Hepatitis C, its efficacy is satisfactory in non-cirrhotic genotype 3 patients (80%) and in non-cirrhotic subtype 1a patients (63.4%).
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Eftychia, Evangelidou
- Ευαγγελίδου, Ευτυχία
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/41004